WuXi Biologics to supply CMC and commercial manufacturing for I-Mab

WuXi Biologics expanded its partnership with I-Mab to include biologics process development and clinical and commercial manufacturing of at least six undisclosed programs.

WuXi Biologics Inc. (HKSE:2269) will provide CMC services for at least five clinical programs and commercial manufacturing for at least one program for I-Mab Biopharma (Shanghai, China). Details were not disclosed...